Access the full text.
Sign up today, get DeepDyve free for 14 days.
Sonia Anand, S. Yusuf, J. Pogue, J. Weitz, M. Flather (1998)
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.Circulation, 98 11
J. Hirsh, R. Raschke, T. Warkentin, J. Dalen, D. Deykin, L. Poller (1992)
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.Chest, 102 4 Suppl
(2000)
non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee on the management of patients with unstable angina)Circulation, 102
Hidenori Urata, Bernadine Healy, Robert Stewart, F. Bumpus, Ahsan Husain (1990)
Angiotensin II-forming pathways in normal and failing human hearts.Circulation research, 66 4
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
W. Stigelman, P. D. (1986)
Goodman and Gilman's the Pharmacological Basis of TherapeuticsMilitary Medicine, 151
G. Stone, B. McLaurin, David Cox, Michel Bertrand, A. Lincoff, Jeffrey Moses, Harvey White, S. Pocock, James Ware, F. Feit, P. Aylward, Angel Cequier, W. Desmet, R. Ebrahimi, M. Hamon, L. Rasmussen, H. Rupprecht, J. Hoekstra, R. Mehran, E. Ohman (2006)
Bivalirudin for patients with acute coronary syndromes.The New England journal of medicine, 355 21
K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Rydén, H. Wedel (1992)
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)The New England journal of medicine, 327 10
D. Mukherjee, J. Fang, S. Chetcuti (2004)
Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromesCirculation, 109
John O'Sullivan, R. Conroy, K. Robinson, N. Hickey, R. Mulcahy (1991)
In-Hospital Prognosis of Ppatients With Fasting Hyperglycemia After First Myocardial InfarctionDiabetes Care, 14
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
J. Ferguson, R. Califf, E. Antman, Marc Cohen, C. Grines, S. Goodman, D. Kereiakes, A. Langer, K. Mahaffey, C. Nessel, P. Armstrong, Á. Avezum, P. Aylward, R. Becker, L. Biasucci, S. Borzak, J. Col, M. Frey, E. Fry, D. Gulba, S. Guneri, E. Gurfinkel, R. Harrington, J. Hochman, N. Kleiman, M. Leon, J. López-Sendón, C. Pepine, W. Rużyłło, S. Steinhubl, P. Teirstein, L. Toro-Figueroa, H. White (2004)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.JAMA, 292 1
D. Mann, A. Deswal (2003)
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.The New England journal of medicine, 349 20
E. Ellerbeck, S. Jencks, M. Radford, T. Kresowik, A. Craig, J. Gold, H. Krumholz, R. Vogel (1995)
Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project.JAMA, 273 19
J. Herlitz, Å. Hjalmarson (1985)
Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.European heart journal, 6 3
Isis Investigation (1987)
Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarctionEuropean Heart Journal, 8
K. Malmberg, A. Norhammar, H. Wedel, L. Rydén (1999)
Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in
L. Wallentin, J. Ohlsson, E. Swahn, E. Karlsson, L. Lundin, F. Landgren, H. Saetre, B. Adren, E. Enghoff, T. Lundstrom, Å. Hjalmarsson, R. Nordlander, B. Andrén, P. Blomstrand, P. Venge, A. Siegbahn, G. Almroth, C. Johansson, A. Normark, K. Wiklund, E. Logander, G. Lindstrom, E. Svensson, S. Undeland (1996)
Low-molecular-weight heparin during instability in coronary artery diseaseThe Lancet, 347
Thomas Tsai, B. Nallamothu, D. Mukherjee, M. Rubenfire, Jianming Fang, P. Chan, E. Kline-Rogers, Amisha Patel, D. Armstrong, K. Eagle, A. Goldberg (2005)
Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoproteinThe American journal of cardiology, 96 11
(1994)
Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto MiocardicoLancet, 343
T. Thom, Nancy Haase, W. Rosamond, V. Howard, J. Rumsfeld, T. Manolio, Zhi‐Jie Zheng, K. Flegal, Christopher O'Donnell, S. Kittner, D. Lloyd‐Jones, D. Goff, Yuling Hong, R. Adams, G. Friday, K. Furie, P. Gorelick, B. Kissela, J. Marler, J. Meigs, V. Roger, S. Sidney, P. Sorlie, J. Steinberger, S. Wasserthiel-Smoller, M. Wilson, P. Wolf (2006)
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation, 113 6
T. Gundersen, J. Kjekshus (1985)
Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarction.Hormone and metabolic research. Supplement series, 15
A. Meijer, F. Verheugt, C. Werter, K. Lie, J. Pol, M. Eenige (1993)
Aspirin Versus Coumadin in the Prevention of Reocclusion and Recurrent Ischemia After Successful Thrombolysis: A Prospective Placebo‐Controlled Angiographic Study Results of the APRICOT StudyCirculation, 87
(1985)
The MIAMI Trial Research GroupEur Heart Journal, 6
J. Dormandy, B. Charbonnel, D. Eckland, E. Erdmann, M. Massi-Benedetti, I. Moules, A. Skene, M. Tan, P. Lefèbvre, G. Murray, E. Standl, R. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R. Heine, L. Koranyi, M. Laakso, M. Mokáň, A. Norkus, V. Pīrāgs, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Škrha, U. Smith, J. Tatoň (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 366
M. Sabatine, C. Cannon, C. Gibson, J. López-Sendón, G. Montalescot, P. Théroux, M. Claeys, F. Cools, K. Hill, A. Skene, C. Mccabe, E. Braunwald (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.The New England journal of medicine, 352 12
S. Yusuf, J. Pogue, Sonia Anand, G. Tognoni, K. Fox, R. Diaz, E. Paolasso, D. Hunt, J. Varigos, Á. Avezum, L. Piegas, C. Joyner, P. Théroux, H. Rupprecht, T. Wittlinger, N. Karatzas, M. Keltai, E. Sitkei, D. Halon, Lewis Bs, Franzosi Mg, M. Galli, A. Maggioni, F. Mauri, M. Corrales, A. Budaj, L. Ceremużyński, P. Commerford, M. Flather, Jeffrey Anderson, J. Hirsh, J. Cairns, M. Gent, R. Gorlin, J. Willerson, J. Wittes, G. Wyse, P. Auger, Chan Yk, H. Hernandez, M. Kyriakidis, Marquis Jf, B. Mayosi, S. Mehta, M. Natarajan, A. Panju, Ramos-Corrales Ma, C. Rihal, Rupprecht Hj, B. Sussex, W. Wąsek, B. Cracknell, J. Lindeman, J. Mackay, H. Marsh, M. Anderson, M. Sloan, I. Stoica, J. Tucker, F. Cherian, C. Christmas, C. Cuvay, I. Gris, F. Mazur, M. Micks, K. Nair, L. Robinson, S. Seitz, S. Smith, L. Tomic, A. Gafni, A. Lamy, C. Sigouin, J. Brown, L. Cronin, M. Johnston, J. Weitz (2001)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.Journal of the American College of Cardiology, 37 2
R. Collins, R. Peto, M. Flather, S. Parish, P. Sleight, M. Conway, A. Pipilis, C. Baigent, D. Barnett, J. Boissel, A. Budaj, J. Cairns, L. Ceremużyński, Af Cohen, G. Backer, R. Díaz, F. Dienstl, P. Dove, M. Franzosi, M. Genoni, D. Halon, J. Heikkila, C. Hennekens, J. Horgan, D. Hunt, R. Kala, N. Karatzas, A. Keech, M. Keltai, J. Kjekshus, M. Kornitzer, R. Koster, P. Landless, P. Lechleitner, A. Leizorovicz, B. Lewis, L. Lundkvist, S. MacMahon, A. Maggioni, R. Malacrida, T. Meyer, T. Moccetti, D. Ocallaghan, E. Paolasso, L. Piegas, A. Reikvam, P. Ridker, T. Ryan, R. Schroder, R. Seabragomes, Jemr Sousa, G. Tognoni, A. Turpie, Valentin, J. Varigos, H. White, L. Wilhelmsen, K. Woods, S. Yusuf, A. Piombo, La Guzman, Dc Montenegro, G. Irusta, Raymond Schneider, C. Cuneo, B. Chamorro, Gerardo Espinosa, M. Moreno, Mm Rios, R. Doll, K. Fox, D. Julian, P. Meier, E. Sandoya, J. Perez (1995)
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionThe Lancet, 345
R. Adams, G. Friday, K. Furie (2006)
Heart disease and stroke statistics: 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Committee: American Heart AssociationDallas, Texas. Circulation, 113
(1988)
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.Journal of the American College of Cardiology, 12 6 Suppl A
(1987)
ISIS (International Studies of Infarct Survival) pilot studyEur Heart J, 8
M. Blazing, J. Lemos, H. White, K. Fox, F. Verheugt, D. Ardissino, Peter Dibattiste, J. Palmisano, D. Bilheimer, S. Snapinn, K. Ramsey, L. Gardner, V. Hasselblad, M. Pfeffer, E. Lewis, E. Braunwald, R. Califf (2004)
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.JAMA, 292 1
S. Yusuf, J. Pogue, Sonia Anand, G. Tognoni, K. Fox, R. Diaz, E. Paolasso, D. Hunt, J. Varigos, Á. Avezum, L. Piegas, C. Joyner, P. Théroux, H. Rupprecht, T. Wittlinger, N. Karatzasy, M. Keltai, E. Sitkei, D. Halon, B. Lewis, M. Franzosi, M. Galli, A. Maggioni, F. Mauri, M. Ramos-Corrales, A. Budaj, L. Ceremużyński, P. Commerford, M. Flather, Jeffrey Anderson, J. Hirsh, J. Cairns, M. Gent, R. Gorlin, J. Willerson, J. Wittes, G. Wyse, P. Auger, Y. Chan, H. Hernandez, M. Kyriakidis, J. Marquis, B. Mayosi, S. Mehta, M. Natarajan, A. Panju, C. Rihal, B. Sussex, W. Wąsek, B. Cracknell, J. Lindeman, J. Mackay, H. Marsh, M. Anderson, M. Sloan, I. Stoica, J. Tucker, F. Cherian, C. Christmas, C. Cuvay, I. Holadyk-Gris, S. Kotlán, F. Mazur, M. Micks, K. Nair, L. Robinson, S. Seitz, S. Smith, L. Tomic, A. Gafni, A. Lamy, C. Sigouin, J. Brown, L. Cronin, M. Johnston, J. Weitz (2001)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable anginaJournal of the American College of Cardiology, 37
S. Yusuf, S. MacMahon, R. Collins, R. Peto (1988)
EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALSThe Lancet, 331
F. Saab, K. Eagle, E. Kline-Rogers, Jianming Fang, R. Otten, D. Mukherjee (2004)
Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times.The American journal of cardiology, 94 9
B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, Steve Hurley, J. Kleiman, M. Gatlin (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.The New England journal of medicine, 348 14
Grace Investigators (2001)
Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes.American heart journal, 141 2
T. Mclaughlin, S. Soumerai, D. Willison, J. Gurwitz, C. Borbas, E. Guadagnoli, B. McLaughlin, N. Morris, S.‐C. Cheng, P. Hauptman, E. Antman, Linda Casey, R. Asinger, Fredarick Gobel (1996)
Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly.Archives of internal medicine, 156 7
Epic Investigators (1994)
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.The New England journal of medicine, 330 14
Deepak Bhatt, M. Roe, E. Peterson, Yun Li, A. Chen, R. Harrington, A. Greenbaum, P. Berger, C. Cannon, D. Cohen, C. Gibson, J. Saucedo, N. Kleiman, J. Hochman, W. Boden, R. Brindis, W. Peacock, Sidney Smith, C. Pollack, W. Gibier, E. Ohman (2004)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement InitiativeJAMA, 292
E. Braunwald, E. Antman, John Beasley, R. Califf, M. Cheitlin, J. Hochman, Robert Jones, D. Kereiakes, Joel Kupersmith, T. Levin, C. Pepine, J. Schaeffer, E. Smith, David Steward, P. Théroux, R. Gibbons, Joseph Alpert, D. Faxon, V. Fuster, G. Gregoratos, L. Hiratzka, A. Jacobs, Sidney Smith (2002)
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of PatientsJournal of the American College of Cardiology, 40 7
P. White, Janice Thomas, H. Kangro, W. Bruce-Jones, J. Amess, D. Crawford, S. Grover, A. Clare (2001)
Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosisThe Lancet, 358
K. Dickstein, J. Kjekshus (2002)
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trialThe Lancet, 360
E. Boersma, R. Harrington, D. Moliterno, H. White, P. Théroux, F. Werf, A. Torbal, P. Armstrong, L. Wallentin, R. Wilcox, J. Simes, R. Califf, E. Topol, M. Simoons (2002)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 359
L. Wallentin, B. Lagerqvist, S. Husted, F. Kontny, E. Ståhle, E. Swahn (2000)
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trialThe Lancet, 356
Epilog Investigators (1997)
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.The New England journal of medicine, 336 24
R. Mehta, Cecelia Montoye, M. Gallogly, Patricia Baker, A. Blount, J. Faul, Canopy Roychoudhury, S. Borzak, Susan Fox, Mary Franklin, Marge Freundl, E. Kline-Rogers, Thomas Lalonde, M. Orza, R. Parrish, Martha Satwicz, M. Smith, P. Sobotka, Stuart Winston, A. Riba, K. Eagle (2002)
Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative.JAMA, 287 10
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
E. Braunwald, E. Antman, J. Beasley, R. Califf, M. Cheitlin, J. Hochman, Robert Jones, D. Kereiakes, J. Kupersmith, T. Levin, C. Pepine, J. Schaeffer, E. Smith, D. Steward, P. Théroux, R. Gibbons, J. Alpert, K. Eagle, D. Faxon, V. Fuster, T. Gardner, G. Gregoratos, R. Russell, Sidney Smith (2000)
ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendationsCatheterization and Cardiovascular Interventions, 51
C. Carswell, G. Plosker (2012)
BivalirudinDrugs, 62
J. Sebus, Coene Er, Van Ja (1964)
THE SIMIAN CREASE.Lancet, 1 7339
E.F. Ellerbeck, S.F. Jencks, M. Radford (1995)
Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot studyJAMA, 273
H. White, Hirulog, Early Investigators (2001)
Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialThe Lancet, 358
E. Antman, C. Mccabe, E. Gurfinkel, A. Turpie, P. Bernink, D. Salein, A. Luna, K. Fox, J. Lablanche, D. Radley, J. Premmereur, E. Braunwald (1999)
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.Circulation, 100 15
M. Cohen, C. Demers, E. Gurfinkel, A. Turpie, G. Fromell, S. Goodman, A. Langer, R. Califf, K. Fox, J. Premmereur, F. Bigonzi, Jim Stephens, B. Weatherley (1997)
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.The New England Journal of Medicine, 337
G.G. Schwartz, A.G. Olsson, M.E. Ezekowitz (2001)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trialJAMA, 285
J. Gurwitz, R. Goldberg, Z. Chen, J. Gore, J. Alpert (1992)
Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly.The American journal of medicine, 93 6
Zhengming Chen, H. Pan, Yiping Chen, R. Peto, R. Collins, Lixin Jiang, J. Xie, Lisheng Liu, Commit (2005)
Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 366
E. Topol (1998)
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 352
C. Gibson, D. Morrow, S. Murphy, T. Palabrica, L. Jennings, P. Stone, Henry Lui, T. Bulle, N. Lakkis, R. Kovach, D. Cohen, P. Fish, C. Mccabe, E. Braunwald (2006)
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.Journal of the American College of Cardiology, 47 12
J.L. Petersen, K.W. Mahaffey, V. Hasselblad (2004)
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJAMA, 292
H.D. White, P. Aylward, M.J. Frey (1997)
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial InvestigatorsCirculation, 96
E. Keeley, J. Boura, C. Grines (2003)
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 361
B. Charbonnier, I. Fotiadis, M. Keltai, A. Leizorovicz, M. Marzilli, R. Masiá, T. Moccetti, M. Renard, Z. Sadowski, R. Seabra‐Gomes, J. Špác, J. Meer, S. Varshavsky, R. Vincent (1999)
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).European heart journal, 20 21
J. Colwell, R. Nesto (2003)
The platelet in diabetes: focus on prevention of ischemic events.Diabetes care, 26 7
M. Pfeffer, J. McMurray, E. Velazquez, J. Rouleau, L. Køber, A. Maggioni, S. Solomon, K. Swedberg, F. Werf, H. White, J. Leimberger, M. Henis, Susan Edwards, S. Zelenkofske, M. Sellers, R. Califf (2003)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.The New England journal of medicine, 349 20
J. Bittl, J. Strony, J. Brinker, W. Ahmed, C. Meckel, B. Chaitman, J. Maraganore, E. Deutsch, B. Adelman, B. Adelman (1995)
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.The New England journal of medicine, 333 12
Å. Hjalmarson, J. Herlitz, I. Málek, L. Rydén, A. Vedin, A. Waldenström, H. Wedel, D. Elmfeldt, S. Holmberg, G. Nyberg, K. Swedberg, F. Waagstein, J. Waldenström, L. Wilhelmsen, C. Wilhelmsson (1981)
EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised TrialThe Lancet, 318
E. Veys, A. Govaerts, E. Coigne, H. Mielants, A. Verbruggen (1974)
HL-A AND INFECTIVE SACROILEITISThe Lancet, 304
(2004)
El tratamiento hipolipemiante intensivo frente al moderado con estatinas tras síndromes coronarios agudos
(1995)
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative GroupLancet, 345
C. Meuleman (2006)
Comparaison of fondaparinux and enoxaparin in acute coronary syndromes. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators., 2
R. Mehta, T. Ruane, P. McCargar, K. Eagle, E. Stalhandske (2000)
The treatment of elderly diabetic patients with acute myocardial infarction: insight from Michigan's Cooperative Cardiovascular Project.Archives of internal medicine, 160 9
D. Mukherjee, J. Fang, S. Chetcuti (2004)
General cardiology: abstractImpact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromesAcc Current Journal Review, 13
C.I. Carswell, G.L. Plosker (2002)
Bivalirudin: a review of its potential place in the management of acute coronary syndromesDrugs, 62
R.H. Mehta, C.K. Montoye, J. Faul (2004)
Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement from key indicators to process of care and tool useJ Am Coll Cardiol, 43
J. Fenton, F. Ofosu, D. Brezniak, H. Hassouna (1998)
Thrombin and AntithromboticsSeminars in Thrombosis and Hemostasis, 24
R. O'rourke, R. Walsh, V. Fuster (2001)
Hurst's The Heart: Manual of Cardiology
A. Oler, M. Whooley, J. Oler, D. Grady (1996)
Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina: A Meta-analysisJAMA, 276
K. Malmberg, A. Norhammar, H. Wedel (1999)
Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) studyCirculation, 99
Jane Thomas, S. Paranjothy, D. James (2004)
National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean sectionBMJ : British Medical Journal, 328
R.H. Mehta, T.J. Ruane, P.A. McCargar (2000)
The treatment of elderly diabetic patients with acute myocardial infarctionArch Intern Med, 160
C.P. Cannon, E. Braunwald, C.H. McCabe (2004)
Intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med, 350
L. Wallentin, B. Lagerqvist, S. Husted (2000)
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators: fast revascularisation during instability in coronary artery diseaseLancet, 356
W. Klein, A. Buchwald, Stuart Hillis, S. Monrad, G. Sanz, A. Turpie, J. Meer, Eric Olaisson, S. Undeland, K. Ludwig (1997)
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)Circulation, 96 1
F.A. Saab, K.A. Eagle, E. Kline-Rogers (2004)
On behalf of the Michigan Cardiovascular Outcomes Research and Reporting Program of the University of Michigan Cardiovascular Center. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later timesAm J Cardiol, 94
J. Petersen, K. Mahaffey, V. Hasselbladet (2004)
Interventional cardiology: abstractEfficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overview☆Acc Current Journal Review, 13
(1998)
Evaluation of platelet IIb/IIIa inhibitor for stentingLancet, 352
K. Eagle, S. Goodman, Á. Avezum, A. Budaj, C. Sullivan, J. López-Sendón (2002)
Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE)The Lancet, 359
(1997)
IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: the EPILOG InvestigatorsN Engl J Med, 336
M. Rothberg, C. Celestin, L. Fiore, Elizabeth Lawler, J. Cook (2005)
Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and BenefitAnnals of Internal Medicine, 143
Gruppo Miocardico. (1994)
GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarctionThe Lancet, 343
R.M. Sacks, M.A. Pfeffer, L.A. Moye (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsN Engl J Med, 335
J.R. Rogers, J.G. Canto, C.T. Lambrew (2000)
Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999J Am Coll Cardiol, 36
R. Rude, J. Muller, E. Braunwald (1981)
Efforts to limit the size of myocardial infarcts.Annals of internal medicine, 95 6
S. Yusuf, F. Zhao, S. Mehta, S. Chrolavicius, G. Tognoni, K. Fox, Clopidogrel Investigators (2001)
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.The New England journal of medicine, 345 7
Zhengming Chen, Lixin Jiang, Yiping Chen, J. Xie, H. Pan, R. Peto, R. Collins, Lisheng Liu, Commit (2005)
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 366
Wah Cheung, V. Wong, M. Mclean (2006)
The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.Diabetes care, 29 4
H. White, P. Aylward, M. Frey, A. Adgey, R. Nair, W. Hillis, Y. Shalev, Michael Brown, J. French, R. Collins, J. Maraganore, B. Adelman (1997)
Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO)Circulation, 96
S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, J. Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin, C. Joyner, K. Fox (2006)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.The New England journal of medicine, 354 14
A. Lincoff, J. Bittl, R. Harrington, F. Feit, N. Kleiman, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, D. Kereiakes, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.JAMA, 289 7
AndrewJ. Coats (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 360
D. Mukherjee, Jianming Fang, E. Kline-Rogers, R. Otten, K. Eagle (2005)
Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groupsHeart, 91
E. Ronner, Y. Dykun, M. Brand, L. Wieken, M. Simoons (1998)
Platelet glycoprotein IIB/IIIA receptor antagonists: An asset for treatment of unstable coronary syndromes and coronary interventionEuropean Heart Journal, 19
M. Cohen, C. Demers, E. Gurfinkel (1997)
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery diseaseN Engl J Med, 337
M. Simoons, S. Ellis (1997)
A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction.The New England journal of medicine, 336 23
M. Lichtman, J. Spivak, L. Boxer, S. Shattil, E. Henderson (2000)
Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961
Marc Cohen, P. Adams, G. Parry, J. Xiong, Douglas Chamberlain, I. Wieczorek, K. Fox, J. Chesebro, J. Strain, Carmel Keller, Ann Kelly, Gilead Lancaster, Jameela Ali, Rn, R. Kronmal, V. Fuster, Antithrombotic Therapy (1994)
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.Circulation, 89 1
S. Goodman, G. Bozovich, M. Tan, A. Santos, E. Gurfinkel, Marc Cohen, A. Langer (2006)
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.American heart journal, 151 4
C. Cannon, W. Weintraub, L. Demopoulos, R. Vicari, M. Frey, N. Lakkis, Franz‐Josef Neumann, D. Robertson, P. Delucca, Peter Dibattiste, C. Gibson, E. Braunwald (2001)
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.The New England journal of medicine, 344 25
M.A. Blazing, J.A. Lemos, H.D. White (2004)
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial [published erratum appears in JAMA 2004; 292: 1178]JAMA, 292
H.D. White (2001)
On behalf of the Hirulog and Early Reperfusion or Occlusion (HERO-2) Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialLancet, 358
(2000)
ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 51 4
Giorgio Bellodi, V. Manicardi, V. Malavasi, Leonarda Veneri, Giustino Bernini, Paolo Bpssini, Salvatore Distefano, G. Magnanini, L. Muratori, Gianni Rossi, A. Zuarini (1989)
Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus.The American journal of cardiology, 64 14
W. Rogers, J. Canto, C. Lambrew, A. Tiefenbrunn, Becky Kinkaid, D. Shoultz, P. Frederick, N. Every (2000)
Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.Journal of the American College of Cardiology, 36 7
E. Gurfinkel, E. Manos, R. Mejaíl, M. Cerdá, E. Duronto, Claudio García, A. Daroca, B. Mautner (1995)
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.Journal of the American College of Cardiology, 26 2
S. Yusuf, P. Sleight, Paulo Rossi, D. Ramsdale, R. Peto, Lynette Furze, H. Sterry, Marian Pearson, Ramesh Motwani, S. Parish, R. Gray, David BENNETrr, C. Bray (1983)
Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction.Circulation, 67 6 Pt 2
T.J. McLaughlin, S.B. Soumerai, D.J. Wilson (1996)
Adherence to national guidelines for drug treatment of suspected acute myocardial infarctionArch Intern Med, 156
C. Cannon (1999)
Diagnosis and management of patients with unstable angina.Current Problems in Cardiology, 24
G. Schwartz, A. Olsson, M. Ezekowitz, P. Ganz, M. Oliver, D. Waters, A. Zeiher, B. Chaitman, S. Leslie, Theresa Stern (2001)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.Indian heart journal, 53 2
S. Yusuf (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. CommentaryThe Lancet, 360
J. Fenton (1995)
Thrombin functions and antithrombotic intervention.Thrombosis and haemostasis, 74 1
D. Kong, R. Califf, David Miller, D. Moliterno, H. White, R. Harrington, J. Tcheng, A. Lincoff, V. Hasselblad, E. Topol (1998)
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.Circulation, 98 25
Acute coronary syndromes (ACS) present a major health challenge in modern medicine. With new clinical trials being conducted, our knowledge of latest therapies for ACS continually evolves. In this article, we review currently available medical therapies and provide evidence-based rationale for current pharmacologic therapies. Among the antiplatelet therapies, aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors demonstrate significant efficacy in reducing morbidity and mortality. Among the anticoagulants, unfractionated heparin and low molecular weight heparin, particularly enoxaparin sodium, remain the hallmarks of therapy against which newer anticoagulants are often compared. Bivalirudin has recently showed significant efficacy in decreasing cardiovascular events and mortality, but with potentially less risk of bleeding than heparin. Results of trials evaluating warfarin remain inconsistent regarding potential benefits. Finally, fondaparinux sodium, recently tested, shows promise as a powerful yet safe anticoagulant. Fibrinolysis is an acceptable modality for reperfusion if facilities equipped for primary percutaneous revascularization are not available. Regarding anti-ischemic therapy, β-adrenoceptor antagonists and nitrates remain critical in the early management of ACS. Inhibitors of the renin-angiotensin-aldosterone system have also shown significant reductions in the morbidity and mortality of patients presenting with ACS, particularly in patients with left ventricular dysfunction and clinical heart failure, with ACE inhibitors being first-line agents and angiotensin receptor antagonists being a reasonable substitute if ACE inhibitors are not tolerated. Among the lipid-lowering therapies, statins (HMG-CoA reductase inhibitors) have been documented as being the most well tolerated and most efficacious therapies for ACS patients and data exist that they should be administered early in ACS management. Studies evaluating combination therapy (antiplatelet drugs, β-adrenoceptor antagonists, ACE inhibitors, and lipid-lowering agents) show a clear benefit in mortality in patients with known coronary artery disease. Efforts to improve these key evidence-based medical therapies are numerous and include such programs as the American College of Cardiology’s Guidelines Applied in Practice, international patient registries such as the Global Registry of Acute Coronary Events, and studies such as CRUSADE. Finally, patients with diabetes mellitus pose a challenge to clinicians both in terms of their glycemic control and in their apparent relative resistance to antiplatelet therapy. Studies involving ACS patients suggest that stringent glycemic control may result in benefits in both morbidity and mortality.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.